To start a GLP-1 telehealth business, split it in two. Your brand owns marketing, customer experience and the management company. Licensed physicians own every exam and prescription, licensed in the state where each patient is located, inside a professional entity they control. Then settle which drug you can lawfully source and how you may advertise it.
The brand and the practice are two different businesses
To the customer, a GLP-1 brand is one company. Legally it is two. One sells: the funnel, the brand, the subscription, the support team, the ad account. The other practices medicine: it evaluates the patient, decides whether a GLP-1 is appropriate, writes the prescription and owns the chart.
You can own the first outright. In most states you cannot own the second unless you hold the license. California states the principle in Business and Professions Code 2400: corporations and other artificial legal entities have no professional rights, privileges or powers. States differ in how strictly they apply it, but the national answer for a founder who is not a physician is usually the same: a physician-owned professional corporation (PC) provides the medical services, and your management services organization (MSO) provides everything else for a fee. How a friendly PC and MSO fit together covers the documents.
The structure only holds if the physician’s control is real. The PC decides who is treated and with what. Your MSO does not set approval rates, write clinical protocols or override a decline.
Licensure follows the patient
The physician has to be licensed where the patient is sitting at the time of the encounter. North Dakota put it in statute: “The practice of medicine is deemed to occur in the state the patient is located” (N.D. Cent. Code 43-17-02.3). A practitioner treating a North Dakota patient “shall possess an active North Dakota license.”
Some states offer a narrower path. Florida lets a professional not licensed in Florida treat a Florida patient by telehealth if that professional registers with the applicable board (Fla. Stat. 456.47(4)). Either way, your state footprint equals your physicians’ license footprint. You cannot market into a state where no eligible physician can review the order. Licensure follows the patient runs through the state variations.
Synchronous or asynchronous is a state-by-state answer
Weight-loss brands want an asynchronous intake: the patient completes a form, a physician reviews it later, no video call. Some states allow it. Florida defines telehealth to include “synchronous or asynchronous telecommunications technology” and lets the evaluation happen by telehealth when it is sufficient to diagnose and treat (Fla. Stat. 456.47(1)(b), (2)).
Others do not. Kentucky says an “electronic, on-line, or telephonic evaluation by questionnaire is inadequate for the initial evaluation of the patient or for any follow-up evaluation” (KRS 311.597(1)(e)). The follow-up clause reaches your refill flow, not only the first visit.
The common thread in the states we have verified: the prescriber establishes a relationship and performs a real evaluation, a good faith exam, before prescribing. A form that auto-approves is the design boards and reviewers single out. Asynchronous telehealth by state sorts the states into permissive, conditional and synchronous-only.
GLP-1s are not controlled substances, so the federal telemedicine rules for controlled drugs do not govern this product line. If you later add a controlled drug to the menu, those rules apply on top of state law.
Your drug decides your margin and your risk
You have two sourcing paths. FDA-approved products, such as Zepbound (tirzepatide), approved November 8, 2023 for chronic weight management, are dispensed through licensed pharmacies. Compounded versions are the second path, and it narrowed sharply.
FDA’s page on compounders, current as of April 1, 2026, gives the dates. The tirzepatide shortage was resolved December 19, 2024, and the semaglutide shortage on February 21, 2025. Enforcement discretion ended for 503B outsourcing facilities on March 19, 2025 for tirzepatide and May 22, 2025 for semaglutide. For 503A pharmacies, the dates ran to the court rulings denying preliminary injunctions: March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide.
A 503A pharmacy may not compound regularly or in inordinate amounts drugs that are “essentially copies of a commercially available drug product” (21 U.S.C. 353a(b)(1)(D)). The exception is a change made for an identified patient that produces a significant difference for that patient, as determined by the prescriber (353a(b)(2)). Price is not a clinical difference. On May 1, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list (91 FR 23431). Comments closed July 30, 2026. As of October 2026, we found no final action published in the Federal Register.
Your pharmacy must also be licensed or registered in every state it ships to. Florida, for example, requires any out-of-state pharmacy that ships a dispensed drug into Florida to register with its board (Fla. Stat. 465.0156(1)). Compounded GLP-1s after the shortage lists the questions to put to a pharmacy.
Advertising runs through LegitScript
Paid acquisition has a gate. Google’s healthcare and medicines policy requires telemedicine advertisers in the US to hold LegitScript Healthcare Merchant Certification and to be certified with Google. LegitScript reviews your licensure coverage, your prescribing model, your pharmacy and your claims. Calling a compounded drug “generic Wegovy” or “FDA-approved” is the fastest way to fail. What LegitScript reviewers check for GLP-1 brands has the copy table and checklist. Other ad platforms and card processors set their own rules, so read each one before you budget.
What a white-label clinical partner supplies
“White label telehealth” usually means you rent the clinical side. A real partner supplies three things: physicians licensed in the states you sell into, the PC structure and management agreement those physicians practice through, and a platform that routes each patient to an eligible physician, records the exam and sends the prescription to the pharmacy.
That is what MDside supplies to online and DTC brands: the physicians, the professional entity and the platform, with your brand on the front end. What a partner should not sell you is an approval rate. A physician who cannot decline is not reviewing, and that is the first thing a board or LegitScript looks for.
What drives the cost of starting
A handful of drivers set what it costs to start a telehealth company. The number of states you launch in decides how many licenses you need. Your sourcing path decides your drug cost and pharmacy terms. Synchronous states add physician time per patient. LegitScript certification, ad platform certification, malpractice coverage, the professional entity filings and the platform itself each add a line. Launching in fewer states first is the main lever you control.
The launch sequence
- Pick your first states, and confirm physicians licensed or registered in each.
- Sort those states by modality: asynchronous permitted, conditional, or synchronous required.
- Form or contract the professional entity, and sign the management services agreement with your MSO.
- Choose the drug: FDA-approved product, or compounded with a documented patient-specific basis.
- Contract a pharmacy licensed in every ship-to state, and get its basis for supply in writing.
- Build intake and exam flows per state, with a decline path that refunds or never charges.
- Write claims that survive review, then apply for LegitScript and platform certification.
- Launch paid traffic only to certified domains, in states where the first seven steps are done.
What this means for you
Build the clinical side first and the funnel second. Choose your launch states, confirm physicians licensed in each, and match your intake to each state’s modality rule before you write ad copy. Settle the drug and the pharmacy in writing, and assume compounded supply needs a patient-specific basis the prescriber documents. Then apply for LegitScript before you spend on ads. If you would rather rent the clinical layer than build it, MDside supplies the physicians, the PC structure and the platform.
Related reading
Frequently asked questions
How do I start a GLP-1 telehealth business?
Separate the brand from the practice. You own marketing and a management company. Physicians licensed where each patient is located perform the exam and prescribe, through a professional entity they control. Then choose an FDA-approved or lawfully compounded drug, a pharmacy licensed in every ship-to state, and get LegitScript certification before running paid ads.
What is white label telehealth for weight loss?
It is an arrangement where a clinical partner supplies the licensed physicians, the professional entity and the prescribing platform, while your brand runs the customer experience. The physicians make every clinical decision, including declines. A partner that promises a fixed approval rate is promising that no real review happens, which exposes your brand and the physicians.
How much does it cost to start a telehealth company?
It depends on drivers more than a single number: how many states you launch in, which drug you source, whether your states require live video, LegitScript and ad platform certification, malpractice coverage, entity formation and your platform. Launching in fewer states first is the biggest lever on startup cost.
Can a GLP-1 telehealth company use asynchronous visits?
In some states. Florida’s telehealth statute covers asynchronous technology and lets the evaluation occur by telehealth when sufficient to diagnose and treat. Kentucky says a questionnaire evaluation is inadequate for initial or follow-up visits. Wherever you sell, the evaluation has to come from a physician licensed where the patient is located.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.